Literature DB >> 8167381

The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study.

S Kawazu1, S Tomono, M Shimizu, N Kato, T Ohno, C Ishii, K Murata, T Watanabe, K Negishi, M Suzuki.   

Abstract

To clarify the relationship between early diabetic nephropathy and the glycemic control in non-insulin-dependent diabetes mellitus (NIDDM) without hypertension, excretion of urinary albumin was studied retrospectively for 8 years. The patients with early diabetic nephropathy were divided into two groups according to the initial urinary albumin index (UAI: mg/g.creatinine), namely, a normoalbuminuric (less than 15 mg/g.creatinine) and a microalbuminuric group (15 < or = UAI < 200 mg/g.creatinine). Comparisons of changes in UAI were made between good (HbA1 < 9.0% and fasting plasma glucose (FPG) < 140 mg/100 mL throughout the observation period) and poor glycemic control groups after 4 and 8 years. In the patients with normoalbuminuria at the initial determination, five of 11 patients (45.5%) with good glycemic control and 14 of 22 patients (63.6%) with poor glycemic control became microalbuminuric after 8 years, respectively (p < 0.05). In the microalbuminuric patients, five of ten patients (50%) with poor glycemic control became macroalbuminuric (UAI > or = 200 mg/g.creatinine), although only one case worsened of five patients with good glycemic control (p < 0.05). In conclusion, the development or progression of early diabetic nephropathy in NIDDM was significantly inhibited by good glycemic control (FPG < 140 mg/100 mL and HbA1 < 9.0%), independent of hypertension, and probably irrespective of the mode of therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167381     DOI: 10.1016/1056-8727(94)90005-1

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  8 in total

1.  Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.

Authors:  Faramarz Ismail-Beigi; Timothy E Craven; Patrick J O'Connor; Diane Karl; Jorge Calles-Escandon; Irene Hramiak; Saul Genuth; William C Cushman; Hertzel C Gerstein; Jeffrey L Probstfield; Lois Katz; Ulrich Schubart
Journal:  Kidney Int       Date:  2011-12-14       Impact factor: 10.612

Review 2.  Glycemic control and burnt-out diabetes in ESRD.

Authors:  Csaba P Kovesdy; Jong C Park; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2010-03-30       Impact factor: 3.455

Review 3.  Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Authors:  Steven G Coca; Faramarz Ismail-Beigi; Nowreen Haq; Harlan M Krumholz; Chirag R Parikh
Journal:  Arch Intern Med       Date:  2012-05-28

Review 4.  Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects.

Authors:  Bancha Satirapoj
Journal:  Kidney Dis (Basel)       Date:  2017-04-08

Review 5.  Diabetic nephropathy among Mexican Americans.

Authors:  Subrata Debnath; Farook Thameem; Tahira Alves; Jacqueline Nolen; Hania Al-Shahrouri; Shweta Bansal; Hanna E Abboud; Paolo Fanti
Journal:  Clin Nephrol       Date:  2012-04       Impact factor: 0.975

Review 6.  Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease.

Authors:  Frederiek E Vos; John B Schollum; Robert J Walker
Journal:  NDT Plus       Date:  2011-12

Review 7.  Comprehensive approach to diabetic nephropathy.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Res Clin Pract       Date:  2014-09-10

Review 8.  Glycated Albumin Versus HbA1c in the Evaluation of Glycemic Control in Patients With Diabetes and CKD.

Authors:  Ting Gan; Xin Liu; Gaosi Xu
Journal:  Kidney Int Rep       Date:  2017-11-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.